

Appendix 4E

Preliminary final report for the financial year ended 30 June 2020

Name of entity

VECTUS BIOSYSTEMS LIMITED ABN: 54 117 526 137**Reporting period:** 30 June 2020**Previous period:** 30 June 2019**Results for announcement to the market**

				\$A
Revenues from ordinary activities	up from	\$220	to	\$51,186
Loss from ordinary activities after tax attributable to members	up	88%	to	(2,996,071)
Loss for the period attributable to owners of Vectus Biosystems Limited	up	88%	to	(2,996,071)

Dividends (distributions)	Amount per security	Franked amount per security
	Final dividend	Nil ¢
Previous corresponding period	Nil ¢	Nil ¢

Brief explanation of the above

The Group has incurred an operating loss of \$2,996,071 for the year ended 30 June 2020 (2019: \$1,596,280) and net equity deficit has moved from \$3,729,821 as at 30 June 2019 to \$5,644,613 as at 30 June 2020. The cash balance as at 30 June 2020 was \$2,685,283.

This Appendix 4E should be read in conjunction with the Half Year Financial Report of the Group as at 31 December 2019. It is also recommended that the Appendix 4E be considered together with any public announcements made by the Group since commencement of the 2019-20 financial year in accordance with the continuous disclosure obligations arising under the *Corporations Act 2001*.

NTA backing

Net tangible asset backing per ordinary share

30-Jun-20
cents
(23.86)**30-Jun-19**
cents
(15.96)**Events occurring after Balance Date**

No matter or circumstance has arisen since 30 June 2020 that has significantly affected or may significantly affect the consolidated entities' operations, the results of these operations, or the consolidated entities' state of affairs in future financial years.

Details of entities over which control has been gained or lost during the period

Not Applicable

Foreign Entities details

Not Applicable

Dividends

No dividends were paid or proposed during the financial year.


Audit or Review details

This report is based on audited accounts.

Annual Financial Report

The Vectus Biosystems Limited audited Annual Financial Report for the year ended 30 June 2020 accompanies this announcement. Additional Appendix 4E disclosure requirements can be found in the Directors' Report, the Review of Operations and the 30 June 2020 financial statements and accompanying notes in the Annual Financial Report.

Sign here:


Date: **31 August 2020**

(Director/Company Secretary)

Print name: **Robert J Waring**